8-K: Disc Medicine Q2 2026 Results & Pipeline Update

Disc Medicine reported Q2 2026 financial results, highlighting strong cash position and progress across its hematologic disease pipeline, with key data readouts expected in late 2026.

Summary

• Disc Medicine announced its second quarter 2026 financial results and provided a business update.
• The company completed a Type A meeting with the FDA regarding bitopertin for EPP, aligning on the Phase 3 APOLLO study as a basis for CRL response, with topline data expected in Q4 2026.
• An Expanded Access Program (EAP) for bitopertin was launched for eligible EPP patients.
• Positive clinical data updates were presented for selcodebart (DISC-0974) in myelofibrosis and bitopertin in EPP.
• Enrollment was completed for the RESTORE-PV Phase 2 study of DISC-3405 in polycythemia vera, with initial data expected in Q3 2026.
• The Phase 1b study of DISC-3405 in sickle cell disease is progressing, with initial data expected in Q4 2026.
• The company ended Q2 2026 with approximately $718 million in cash, cash equivalents, and marketable securities, providing runway into 2029.
• Net loss for Q2 2026 was $59.5 million, compared to $55.2 million in Q2 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report due to significant pipeline progress, positive data updates, and a strong cash position providing a long runway, despite an expected increase in net loss.

Positives

• Strong financial position with $717.7 million in cash, cash equivalents, and marketable securities as of June 30, 2026, providing runway into 2029.
• Completed Type A meeting with the FDA for bitopertin, aligning on the Phase 3 APOLLO study as a basis for CRL response.
• Launched Expanded Access Program (EAP) for bitopertin for eligible EPP patients.
• Presented positive clinical data updates for selcodebart in myelofibrosis and bitopertin in EPP.
• Completed enrollment for RESTORE-PV Phase 2 study of DISC-3405 in polycythemia vera ahead of schedule, with initial data expected in Q3 2026.
• EU Orphan Drug Designation received for selcodebart for the treatment of myelofibrosis.
• Major anemia response rate of 56% and overall anemia response rate of 72% observed for selcodebart in myelofibrosis.

Negatives

• Net loss increased to $59.5 million for Q2 2026 from $55.2 million in Q2 2025, primarily due to higher operating costs.
• Research and Development expenses increased to $46.9 million in Q2 2026 from $46.3 million in Q2 2025.
• Selling, General and Administrative expenses increased to $18.1 million in Q2 2026 from $15.1 million in Q2 2025.

Risks

• The results of preclinical studies and clinical trials may not be predictive of future results and may not support further development and marketing approval.
• The timing and anticipated results of clinical trials are subject to change.
• Regulatory authorities, including the FDA, may not make timely decisions or may not approve the company's product candidates.
• The company may not be able to identify additional product candidates with significant commercial potential.
• Adequacy of capital to support future operations and ability to successfully initiate and complete clinical trials.
• New risks and uncertainties may emerge from time to time.

Future Outlook

The company anticipates significant advancements across its pipeline in the second half of 2026, including topline data from the Phase 3 APOLLO trial of bitopertin in Q4 2026, initial data from DISC-3405 studies in Q3 and Q4 2026, and an end-of-Phase 2 meeting with the FDA for selcodebart by year-end. The company expects to potentially advance two more programs into pivotal-stage development in 2027.

Management Comments

• "The anticipated readout of the Phase 3 APOLLO trial of bitopertin in EPP in Q4 marks a significant milestone. We have continued driving forward on this program over the past quarter with the launch of our EAP," said John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc.
• "We also look forward to significant advancement across the rest of our pipeline in the second half of 2026."
• "We saw strong demand for the Phase 2 RESTORE-PV trial of DISC-3405 in polycythemia vera, which is now fully enrolled with initial data coming ahead of schedule in Q3."
• "Along with an expected end of Phase 2 FDA interaction on selcodebart in MF anemia in Q4, we will potentially be positioned to advance two more programs into pivotal-stage development in 2027."

Industry Context

StockSavvy.ai notes that Disc Medicine is operating in the highly competitive and capital-intensive biopharmaceutical sector, focusing on rare hematologic diseases. The company's progress with multiple clinical-stage assets, particularly bitopertin and selcodebart, positions it to address significant unmet medical needs. The strong cash position is crucial for navigating the lengthy and expensive drug development process.

Comparison to Industry Standards

• The anemia response rates for selcodebart (56% major, 72% overall) in myelofibrosis appear competitive compared to existing therapies, though direct comparisons require specific trial designs and patient populations.
• The cash runway into 2029 is a strong positive, exceeding the typical 18-24 month runway often seen in clinical-stage biotechs, providing significant operational flexibility.
• The company's strategy of advancing multiple candidates in parallel is common among biopharma firms aiming to de-risk their pipeline and maximize potential value.

Stakeholder Impact

• Shareholders: Positive outlook due to pipeline progress and strong cash position, but increased net loss may be a concern.
• Patients: Potential benefit from Expanded Access Program for bitopertin and continued development of novel treatments for hematologic diseases.
• Employees: Increased headcount suggests continued investment and growth within the company.
• Creditors: Strong cash position reduces immediate concerns regarding financial solvency.

Next Steps

• Report topline data from the Phase 3 APOLLO study of bitopertin in Q4 2026.
• Report initial data from the RESTORE-PV Phase 2 study of DISC-3405 in Q3 2026.
• Report initial data from the Phase 1b study of DISC-3405 in sickle cell disease in Q4 2026.
• Present additional data from the RALLY-MF trial of selcodebart in Q4 2026.
• Hold an end-of-Phase 2 meeting with the FDA for selcodebart by year-end 2026.
• Potentially advance two more programs into pivotal-stage development in 2027.
• Report initial data from the Phase 2 study of selcodebart in inflammatory bowel disease in 2027.

Key Dates

Recommendation

The company is making good progress on its pipeline with positive data emerging and a strong cash position. However, the increased net loss and the inherent risks in drug development, including regulatory approvals and trial outcomes, warrant a 'hold' recommendation until further de-risking events occur, such as successful pivotal trial readouts or regulatory approvals.

Keywords

Bitopertin, Selcodebart, DISC-3405, Erythropoietic Protoporphyria, Myelofibrosis, Polycythemia Vera, Sickle Cell Disease, Hematologic Diseases